Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies

被引:50
作者
Frumovitz, Michael
Sood, Anil K.
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA
关键词
vascular endothelial growth factor (VEGF); angiogenesis; gynecologic cancer;
D O I
10.1016/j.ygyno.2006.10.062
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Vascular endothelial growth factor (VEGF) plays a critical role in angiogenesis, which is required for tumor growth and metastasis. In this article, a review of the functional and biological roles of the VEGF pathway in driving angiogenesis and growth of gynecologic malignancies was performed. Based on the biological functions of VEGF, multiple approaches for targeting the VEGF/VEGF-receptor complex have been developed and many of these have demonstrated substantial activity in preclinical models. These promising data have led to rapid clinical development of VEGF-targeted agents. Therefore, we also assessed the status of VEGF-targeted therapies and associated toxicities in gynecologic malignancies. However, many questions remain related to optimal dosing, sequencing of therapies, management of toxicities, appropriate patient selection, and assessment of response, which will require further studies. Nevertheless, VEGF-targeted therapies offer hope for improving the outcome of cancer patients. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:768 / 778
页数:11
相关论文
共 81 条
[1]   VASCULAR ENDOTHELIAL GROWTH-FACTOR ACTS AS A SURVIVAL FACTOR FOR NEWLY FORMED RETINAL-VESSELS AND HAS IMPLICATIONS FOR RETINOPATHY OF PREMATURITY [J].
ALON, T ;
HEMO, I ;
ITIN, A ;
PEER, J ;
STONE, J ;
KESHET, E .
NATURE MEDICINE, 1995, 1 (10) :1024-1028
[2]   Tumorigenesis and the angiogenic switch [J].
Bergers, G ;
Benjamin, LE .
NATURE REVIEWS CANCER, 2003, 3 (06) :401-410
[3]   Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].
Bergers, G ;
Song, S ;
Meyer-Morse, N ;
Bergsland, E ;
Hanahan, D .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295
[4]   Sustained response to bevacizumab in refractory well-differentiated ovarian neoplasms [J].
Bidus, Michael A. ;
Webb, Joel C. ;
Seidman, Jeffrey D. ;
Rose, G. Scott ;
Boice, Charles R. ;
Elkas, John C. .
GYNECOLOGIC ONCOLOGY, 2006, 102 (01) :5-7
[5]  
Burger RA, 2005, J CLIN ONCOL, V23, p457S
[6]  
Byrne AT, 2003, CLIN CANCER RES, V9, P5721
[7]  
CANNISTRA S, 2006, J CLIN ONCOL, P5006
[8]   Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions [J].
Carmeliet, P ;
Moons, L ;
Luttun, A ;
Vincenti, V ;
Compernolle, V ;
De Mol, M ;
Wu, Y ;
Bon, F ;
Devy, L ;
Beck, H ;
Scholz, D ;
Acker, T ;
DiPalma, T ;
Dewerchin, M ;
Noel, A ;
Stalmans, I ;
Barra, A ;
Blacher, S ;
Vandendriessche, T ;
Ponten, A ;
Eriksson, U ;
Plate, KH ;
Foidart, JM ;
Schaper, W ;
Charnock-Jones, DS ;
Hicklin, DJ ;
Herbert, JM ;
Collen, D ;
Persico, MG .
NATURE MEDICINE, 2001, 7 (05) :575-583
[9]   A HIGH-SPEED INGAASP/INP DFB LASER WITH AN AIR BRIDGE CONTACT CONFIGURATION [J].
CHEN, TR ;
CHEN, PC ;
GEE, C ;
BARCHAIM, N .
IEEE PHOTONICS TECHNOLOGY LETTERS, 1993, 5 (01) :1-3
[10]   Vascular endothelial growth factor and prognosis of cervical carcinoma [J].
Cheng, WF ;
Chen, CA ;
Lee, CN ;
Wei, LH ;
Hsieh, FJ ;
Hsieh, CY .
OBSTETRICS AND GYNECOLOGY, 2000, 96 (05) :721-726